MetLife stock: UK life business sale reshapes portfolio focus
Published on 11/16/2026 at 16:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat the UK transaction changes
- MetLife agreed to sell its closed-book UK life business to Chesnara, subject to regulatory approval.
- MetLife will retain its ongoing UK protection business and continue servicing those customers.
- The transaction adds a portfolio change alongside the insurer's capital and funding priorities.
MetLife has agreed to sell its closed-book UK life insurance business to Chesnara, adding a material portfolio transaction to the insurer's recent corporate developments. The transaction was reported in the Nov. 6-10 period by Stockrow.
What the transaction includes
The business comprises about 18,000 policies and GBP 1.7 billion in assets. The sale remains subject to regulatory approval and is expected to close in the first half of 2027.
MetLife will retain its ongoing UK protection business and continue servicing those customers. The structure therefore separates a closed-book operation from the insurer's continuing protection franchise rather than representing a withdrawal from the UK market.
Portfolio and capital context
The transaction follows MetLife's third-quarter report and an amended credit agreement that provides up to USD 4 billion of committed borrowing or letter-of-credit capacity, according to the company's Form 8-K reproduction cited in the latest company coverage. The expanded facility may support general corporate purposes, but the agreement does not show that the full capacity has been drawn.
MetLife stock traded at 92.59 euros on Lang & Schwarz at 16:00 CET on Monday, November 16.
MetLife Inc. stock details
- Company: MetLife Inc.
- ISIN: US59156R1086
- Stock ticker: MET
- Home exchange: New York Stock Exchange
- Quoted price: 92.59 euros on Lang & Schwarz, November 16, 2026, at 16:00 CET
- Industry: Insurance - Life
- Sector: Financial Services
Current market reports provide the broader setting for United States equities: Current market reports.
